-
Product Insights
NewPTCA Drug Coated Balloon (DCB) Catheters Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
PTCA Drug Coated Balloon (DCB) Catheters Pipeline Market Report Overview A Drug Coated Balloon (DCB) Catheter is an anti-restenotic drug coated PTCA balloon catheter intended to prevent re-narrowing of the coronary arteries. The PTCA Drug Coated Balloon (DCB) Catheters pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed...
-
Product Insights
NewLikelihood of Approval Analysis for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
Overview How likely is it that the drugs in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Non Muscle Invasive Bladder Cancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Isuzinaxib in Acute Renal Failure (ARF) (Acute Kidney Injury)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Isuzinaxib in Acute Renal Failure (ARF) (Acute Kidney Injury) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Isuzinaxib in Acute Renal Failure (ARF) (Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dinutuximab in Osteosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dinutuximab in Osteosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dinutuximab in Osteosarcoma Drug Details: Dinutuximab (Unituxin) is a chimeric monoclonal antibody, composed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Dedifferentiated Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Dedifferentiated Liposarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Dedifferentiated Liposarcoma Drug Details: Pembrolizumab (Keytruda) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Pleomorphic Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Pleomorphic Liposarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Pleomorphic Liposarcoma Drug Details: Pembrolizumab (Keytruda) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Ureter Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Ureter Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Ureter Cancer Drug Details: Pembrolizumab (Keytruda) is an antineoplastic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BPC-1 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BPC-1 in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BPC-1 in Metastatic Breast Cancer Drug Details: BPC-1 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Marginal Zone B-cell Lymphoma Drug Details: Pembrolizumab...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Pembrolizumab (Keytruda)...